Amryt Pharma: EIB Funds Secure Phase III For Rare Skin Disease Candidate And Cholesterol Drug License
Not many 18-month old rare and orphan disease-focused biotech companies have an approved product in their portfolio. Even fewer have persuaded the European Investment Bank to make a direct investment into their business. Amryt Pharma can claim both.
You may also be interested in...
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Aegerion and QLT will unite to create a new company dubbed Novelion in a deal that could help both companies solve some long-standing issues.
A new orphan drug player - Amryt Pharma Plc- is coming to the London stock market heralding a promising pipeline and experienced leadership, arriving via a reverse takeover with Alternative Investment Market (AIM)-listed investment firm Fastnet Equity PLC.